$1.54
0.01[0.65%]
Last update: 10:45AM Get Real Time Here
Corvus Pharma
(NASDAQ:CRVS)Corvus Pharma Stock (NASDAQ:CRVS), Analyst Ratings, Price Targets, Predictions
Corvus Pharmaceuticals Inc has a consensus price target of $5.75, established from looking at the 14 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, Mizuho, and Oppenheimer on April 1, 2024, March 27, 2024, and March 20, 2024. With an average price target of $3.5 between Cantor Fitzgerald, Mizuho, and Oppenheimer, there's an implied 131.79% upside for Corvus Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
Mizuho
Oppenheimer
Mizuho
Ladenburg Thalmann
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Corvus Pharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/01/2024 | CRVS | Buy Now | Corvus Pharma | $1.51 | — | Cantor Fitzgerald | Li Watsek | — | Reiterates | → Overweight | Get Alert |
| 03/27/2024 | CRVS | Buy Now | Corvus Pharma | $1.51 | 131.79% | Mizuho | Graig Suvannavejh | $3.5 → $3.5 | Maintains | Neutral | Get Alert |
| 03/20/2024 | CRVS | Buy Now | Corvus Pharma | $1.51 | 363.58% | Oppenheimer | Jeff Jones | $8 → $7 | Maintains | Outperform | Get Alert |
| 09/07/2023 | CRVS | Buy Now | Corvus Pharma | $1.51 | 164.9% | Cantor Fitzgerald | Li Watsek | → $4 | Reiterates | Overweight → Overweight | Get Alert |
| 06/16/2023 | CRVS | Buy Now | Corvus Pharma | $1.51 | 131.79% | Mizuho | Mara Goldstein | → $3.5 | Reiterates | Neutral → Neutral | Get Alert |
| 05/30/2023 | CRVS | Buy Now | Corvus Pharma | $1.51 | 562.25% | Ladenburg Thalmann | Aydin Huseynov | $4 → $10 | Maintains | Buy | Get Alert |
| 05/09/2023 | CRVS | Buy Now | Corvus Pharma | $1.51 | 164.9% | Cantor Fitzgerald | Li Watsek | $2 → $4 | Maintains | Overweight | Get Alert |
| 03/30/2023 | CRVS | Buy Now | Corvus Pharma | $1.51 | 131.79% | Mizuho | Mara Goldstein | → $3.5 | Reiterates | → Neutral | Get Alert |
| 10/07/2022 | CRVS | Buy Now | Corvus Pharma | $1.51 | 32.45% | Ladenburg Thalmann | Aydin Huseynov | → $2 | Initiates | → Buy | Get Alert |
| 12/03/2021 | CRVS | Buy Now | Corvus Pharmaceuticals | $1.51 | 429.8% | Cantor Fitzgerald | — | — | Maintains | Overweight | Get Alert |
| 12/01/2021 | CRVS | Buy Now | Corvus Pharmaceuticals | $1.51 | 429.8% | Jefferies | Roger Song | — | Initiates | → Buy | Get Alert |
| 08/03/2021 | CRVS | Buy Now | Corvus Pharmaceuticals | $1.51 | 131.79% | Mizuho | Mara Goldstein | — | Maintains | Neutral | Get Alert |
| 07/16/2021 | CRVS | Buy Now | Corvus Pharmaceuticals | $1.51 | 297.35% | HC Wainwright & Co. | Swayampakula Ramakanth | — | Maintains | Buy | Get Alert |
| 05/27/2021 | CRVS | Buy Now | Corvus Pharmaceuticals | $1.51 | 562.25% | Cantor Fitzgerald | — | — | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Corvus Pharma (CRVS)?
The latest price target for Corvus Pharma (NASDAQ: CRVS) was reported by Cantor Fitzgerald on April 1, 2024. The analyst firm set a price target for $0.00 expecting CRVS to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Corvus Pharma (CRVS)?
The latest analyst rating for Corvus Pharma (NASDAQ: CRVS) was provided by Cantor Fitzgerald, and Corvus Pharma reiterated their overweight rating.
When was the last upgrade for Corvus Pharma (CRVS)?
There is no last upgrade for Corvus Pharma.
When was the last downgrade for Corvus Pharma (CRVS)?
There is no last downgrade for Corvus Pharma.
When is the next analyst rating going to be posted or updated for Corvus Pharma (CRVS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corvus Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corvus Pharma was filed on April 1, 2024 so you should expect the next rating to be made available sometime around April 1, 2025.
Is the Analyst Rating Corvus Pharma (CRVS) correct?
While ratings are subjective and will change, the latest Corvus Pharma (CRVS) rating was a reiterated with a price target of $0.00 to $0.00. The current price Corvus Pharma (CRVS) is trading at is $1.54, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.